暂无数据
代码股票名称
最新价涨跌额涨跌幅成交量成交额今开昨收最高最低总市值流通市值总股本流通股本5日涨跌幅10日涨跌幅20日涨跌幅60日涨跌幅120日涨跌幅250日涨跌幅年初至今涨跌幅股息率TTM换手率市盈率TTM市盈率(静)振幅所属行业
美股期权个股详情
ACAD240517C16000
- 0.05
- -0.13-72.22%
延时15分钟行情交易中 05/13 12:21 (美东)
0.14最高价0.05最低价
0.14今开0.18昨收2张成交量33张未平仓合约数16.00行权价19.00成交额60.57%隐含波动率5.56%溢价2024/05/17到期日0.00内在价值100合约乘数4天距到期日0.05时间价值100合约规模美式期权类型0.2546Delta0.3162Gamma102.00杠杆倍数-0.0386Theta0.0004Rho25.97有效杠杆0.0054Vega
分时
- 5日
- 日K
新闻
分析师提供有关医疗保健公司的见解：C4 Therapeutics（CCCC）、阿卡迪亚制药（ACAD）和Disc Medicine（IRON）
坎托挑选了14只值得一看的被低估的生物技术股票
结果：阿卡迪亚制药公司超出预期，共识已更新其估计
奥本海默将阿卡迪亚制药的目标股价从19美元调整至17美元，维持业绩评级
Capital IQ调查的分析师表示，阿卡迪亚制药公司（ACAD）的平均评级为跑赢大盘，目标股价在13美元至39美元之间。价格：15.45，涨幅：+0.24，变动百分比：+1
分析师对医疗保健公司发表见解：Intellia Therapeutics（NTLA）、Integer Holdings（ITGR）和阿卡迪亚制药（ACAD）
B of A 证券将阿卡迪亚制药维持在中性
B of A 证券将阿卡迪亚制药维持在中性
评论
Analysts have high confidence in ACADIA Pharmaceuticals, predicting an average annual growth rate of 42%. The company's lack of debt reduces concerns around repayments and makes it a less risky investment.
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) On The Verge Of Breaking Even 1
Several companies were in the spotlight due to various developments:
Oracle ( $甲骨文(ORCL.US$ ) experienced a surge in after-hours trading, buoyed by cloud deals and AI demand.
Acadia Pharmaceuticals ( $阿卡迪亚(ACAD.US$ ) saw its stock decline by 15% following the announcement of disappointing results from a Phase 3 trial.
Vail Resorts ( $Vail Resorts(MTN.US$ ) reported a decrease in stock value after releasing results that were impacted by lower visits and snowfall.
$阿莎娜(ASAN.US$ Asana rep...
Oracle ( $甲骨文(ORCL.US$ ) experienced a surge in after-hours trading, buoyed by cloud deals and AI demand.
Acadia Pharmaceuticals ( $阿卡迪亚(ACAD.US$ ) saw its stock decline by 15% following the announcement of disappointing results from a Phase 3 trial.
Vail Resorts ( $Vail Resorts(MTN.US$ ) reported a decrease in stock value after releasing results that were impacted by lower visits and snowfall.
$阿莎娜(ASAN.US$ Asana rep...
2
$阿卡迪亚(ACAD.US$ Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced top-line results from the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia. Pimavanserin did not demonstrate a statistically significant improvement over placebo on the study's primary endpoint, the change from baseline to week 26 on the Negative Symptom Assessment-16 (NSA-16) total score (-11.8 vs. -11.1; p=0.4825; effe...
1
6
阅读更多